help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on August 11, 2005
Molecular Endocrinology, doi:10.1210/me.2005-0127
A more recent version of this article appeared on January 1, 2006
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
20/1/167    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Volinic, J. L.
Right arrow Articles by Thomas, M. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Volinic, J. L.
Right arrow Articles by Thomas, M. K.

Submitted on March 17, 2005
Accepted on August 4, 2005

Overexpression of the Coactivator Bridge-1 Results in Insulin Deficiency and Diabetes

Jamie L. Volinic, Jee H. Lee, Kazuhiro Eto, Varinderpal Kaur, and Melissa K. Thomas*

Laboratory of Molecular Endocrinology and Diabetes Unit, Massachusetts General, Hospital and Harvard Medical School, Boston, Massachusetts, USA

* To whom correspondence should be addressed. E-mail: mthomas1{at}partners.org.

Multiple forms of heritable diabetes are associated with mutations in transcription factors that regulate insulin gene transcription and the development and maintenance of pancreatic {beta}-cell mass. The coactivator Bridge-1 (PSMD9) regulates the transcriptional activation of glucose-responsive enhancers in the insulin gene in a dose-dependent manner via PDZ-domain mediated interactions with E2A transcription factors. Here we report that the pancreatic overexpression of Bridge-1 in transgenic mice reduces insulin gene expression and results in insulin deficiency and severe diabetes. Dysregulation of Bridge-1 signaling increases pancreatic apoptosis with a reduction in the number of insulin-expressing pancreatic {beta} cells and an expansion of the complement of glucagon-expressing pancreatic {alpha} cells in pancreatic islets. Increased expression of Bridge-1 alters pancreatic islet, acinar, and ductal architecture and disrupts the boundaries between endocrine and exocrine cellular compartments in young adult but not neonatal mice, suggesting that signals transduced through this coactivator may influence postnatal pancreatic islet morphogenesis. Signals mediated through the coactivator Bridge-1 may regulate both glucose homeostasis and pancreatic {beta}-cell survival. We propose that coactivator dysfunction in pancreatic {beta} cells can limit insulin production and contribute to the pathogenesis of diabetes.




This article has been cited by other articles:


Home page
ANN INTERN MEDHome page
G. E. Umpierrez, D. Smiley, and A. E. Kitabchi
Narrative review: ketosis-prone type 2 diabetes mellitus.
Ann Intern Med, March 7, 2006; 144(5): 350 - 357.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society